ライフサイエンスコーパス: Doxil

1 v. injected pegylated liposomal doxorubicin (Doxil).

2 that of an equimolar dose of liposomal DOX (Doxil).

3 their combinations, including bortezomib and Doxil.

4 nical studies and by the clinical success of Doxil.

5 macromolecule-based cancer therapies such as Doxil.

6 es C, 5 min) followed 30 min later with i.v. Doxil (1 mg) or Doxil alone.

7 f this combination for further evaluation is Doxil 30 mg/m(2) and docetaxel 60 mg/m(2) given every 3

8 When used with G-CSF, it is Doxil 30 mg/m(2) and docetaxel 75 mg/m(2) every 4 weeks.

9 G-CSF, the MTD was docetaxel 60 mg/m(2) and Doxil 30 mg/m(2) every 3 weeks; only 1 (7%) out of 15 pa

10 n treating the murine C26 colon carcinoma as Doxil, a commercial liposome doxorubicin formulation.

11 ared in the same size as Lip/Gd/DiI-DS, with Doxil, a liposomal drug of similar size used to treat se

12 Doxil, a liposomal formulation of the chemotherapeutic d

13 t given immediately before administration of Doxil, a liposomally encapsulated formulation of doxorub

14 umor ablation sharply increases intratumoral Doxil accumulation over i.v. Doxil alone, enabling a red

15 d muscle loss compared with a single dose of Doxil alone and was as effective as free doxorubicin.

16 received direct injections of 1, 2, or 3 mg Doxil alone or in sequence with other agents directly in

17 es intratumoral Doxil accumulation over i.v. Doxil alone, enabling a reduction of systemic dose while

18 lowed 30 min later with i.v. Doxil (1 mg) or Doxil alone.

19 ouse model, we demonstrate that co-injecting Doxil and a Zirconium-89 nanoreporter ((89)Zr-NRep) allo

20 o clinically useful cancer therapeutics like Doxil and DaunoXome.

21 stant (KB 8-5) tumor models compared to DOX, Doxil, and PEG5K-VE2/DOX.

22 New agents including doxorubicin, Doxil, and ricin mab35 are being developed to create a l

23 ntly higher levels of cytotoxicity over DOX, Doxil as well as PEG5K-VE2/DOX in PC-3 and 4T1.2 cells.

24 To test the safety and effectiveness of Doxil chemomyectomy in monkey eyelids using treatment sc

25 Doxil chemomyectomy is an effective protocol to permanen

26 redicted based on the increase in intratumor Doxil concentration.

27 nanoparticle-based drug delivery platforms (Doxil, DaunoXome, Marqibo, and Abraxane) in the context

28 Higher doses of Doxil did not increase the desired myotoxic effect; appa

29 RF ablation reduced the i.v. Doxil dose needed to achieve intratumoral doxorubicin up

30 The effects of varying i.v. Doxil doses (0.0625-7.0 mg; n = 100) and the RF tip temp

31 Experiments were performed for Doxil, Doxil-like liposomes, and Doxil-like liposomes wi

32 n clinically approved liposomal doxorubicin (Doxil) in HER2-overexpressing BT474 tumor xenograft mode

33 F) ablation with i.v. liposomal doxorubicin (Doxil) increases intratumoral doxorubicin accumulation a

34 All Doxil injections resulted in a significant loss of myofi

35 For the skin, Doxil is classified as an irritant rather than a vesican

36 ulations, such as nanoliposomal doxorubicin (Doxil), is increasingly integrated in clinical cancer ca

37 atumoral penetration of a model nanocarrier (Doxil), leading to enhanced availability of the drug in

38 The combination of PDT and Doxil led to a highly significant potentiation in tumor

39 In contrast a 'Doxil'-like liposome formulation gave no such triggered

40 rformed for Doxil, Doxil-like liposomes, and Doxil-like liposomes with reduced cholesterol and pegyla

41 Experiments were performed for Doxil, Doxil-like liposomes, and Doxil-like liposomes with redu

42 Doxil liposomes are designed to retain doxorubicin in ci

43 ess the kinetics of doxorubicin leakage from Doxil liposomes.

44 Thus, repeated doses of Doxil may prove to be as clinically effective as free do

45 re examined histologically for the effect of Doxil on the orbicularis oculi muscle and the skin.

46 ications for the mechanism of action, taking Doxil pharmacokinetics into account.

47 MRI detection of Lip/Gd coadministered with Doxil provided optimum CED parameters for complete cover

48 c P85 was injected 1h, 48h, or 96h after the Doxil(R) administration in A2780 human ovarian cancer xe

49 posomes and increase therapeutic efficacy of Doxil(R) by administering Pluronic block copolymers once

50 The antitumor efficacy of Doxil(R) is hindered by the poor release of the active d

51 mposition and size to be similar to those of Doxil(R) liposomes.

52 Furthermore, multifunctional immuno-Doxil(R) preparation showed increased cellular cytotoxic

53 est anti-tumor effect of single injection of Doxil(R) was achieved when Pluronic P85 was administered

54 l formulation of liposomal doxorubicin (i.e. DOXIL(R)) and were loaded with barbituric acid (BA), a s

55 -circulating liposomes (HSPC:cholesterol and Doxil(R)), modified with cell-penetrating TAT peptide (T

56 are the preclinical and clinical results for Doxil(R), PK1, Abraxane(R), Genexol-PM(R), Xyotax, NC-60

57 ds the overall survival of mice treated with Doxil(R).

58 nic P85 could facilitate release of Dox from Doxil(R).

59 when Pluronic P85 was administered 48h after Doxil(R).

60 Injection of Doxil resulted in significant reduction of skin injury c

61 with Doxil treatment significantly increased Doxil's myotoxic effects.

62 As a potential alternative therapy, Doxil (Sequus, Menlo Park, CA), a liposome-encapsulated

63 ed 20 mg/m2 pegylated-liposomal doxorubicin (Doxil; Sequus Pharmaceuticals, Inc, Menlo Park, CA) ever

64 However, either two injections of Doxil spaced 2 months apart or preinjury of the lid with

65 ivalent milligram doses of free doxorubicin, Doxil spared the skin from injury.

66 +/- 7.7 microg/g) were seen with combined RF/Doxil therapy (P < 0.01).

67 greater tumor necrosis was identified for RF/Doxil-treated tumors compared with tumors treated with R

68 lid with bupivacaine before a single dose of Doxil treatment resulted in increased muscle loss compar

69 s using the preinjury protocol combined with Doxil treatment significantly increased Doxil's myotoxic

70 cetaxel 75 mg/m(2) every 4 weeks, the MTD of Doxil was 30 mg/m(2) and required granulocyte colony-sti

71 Doxil was only approximately 60% as effective in killing

72 Bupivacaine/hyaluronidase and Doxil were injected sequentially into the eyelids of fiv

73 Although single injections of Doxil were myotoxic, multiple exposure of the eyelid to

74 Infusion reactions were common with Doxil with the recommended infusion schedule during the